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Twenty years have now elapsed since Ashbaugh and Petty first described the syndrome of
acute respiratory failure associated with a wide spectrum ofclinical conditions. During the past
two decades, significant advances have emerged in our understanding of the clinical conditions
associated with the syndrome and the pathophysiological changes affecting the alveolar-
capillary membrane responsible for the characteristic non-cardiogenic pulmonary edema.
Recent data have reaffirmed the notion that mortality rates in ARDS remain in excess of 60
percent, essentially unchanged since the first description of the syndrome, despite all the
advances in critical care medicine in the intervening years.
The incidence of ARDS has been difficult to establish because of lack of agreement on
precise definition criteria. The lack ofagreed definition criteria has hampered evaluation ofthe
natural history of the syndrome, its epidemiology and mortality rates, and the efficacy or
otherwise of a variety oftherapeutic interventions.
This review will highlight a recent, clinically appropriate, expanded definition ofARDS. New
understandings ofthe roles ofsepsis and multi-system organ failure in mortality associated with
ARDS will be discussed. Several mediators, both locally in the lung and in the systemic
circulation, have been implicated in the pathophysiology ofARDS. This review will discuss the
evidence for and against neutrophils, platelets, cytokines derived from mononuclear cells and
macrophages, complement, prostaglandins/leukotrienes, oxygen-derived radicals, and avariety
of proteases.
Current treatment strategies for ARDS are designed to increase tissue oxygen delivery by
increasing arterial oxygen tension and cardiac output while simultaneously attenuating the
pulmonary and systemic injury by appropriate pharmacologic and surgical interventions.
Recent data advocating pharmacological augmentation of cardiac index and oxygen delivery
will be highlighted. The persistently high mortality rates of 60-70 percent in patients with
established ARDS have provoked recurring interest in new techniques ofproviding mechanical
ventilation. Most studies have shown, however, that mortality in ARDS patients is attributable
mainly to sepsis and multi-system organ failure rather than primarily to respiratory failure.
Established and speculative intervention to reduce sepsis and multi-system organ failure
associated with ARDS will be featured in the review.
INTRODUCTION
A syndrome ofrespiratory dysfunction, characterized by severe hypoxemia, patchy
bilateral pulmonary infiltrates on chest X-ray, and low pulmonary compliance was
described by Ashbaugh and Petty in the Lancet in 1967 [1]. The terms "shock lung,"
"Da Nang lung," and others applied to the syndrome in the late 1960s and early
1970s have been replaced by the now universal description of adult respiratory
distress syndrome (ARDS). ARDS has become widely used to convey the clinical
manifestations of the effects of increased permeability of the alveolar-capillary
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failure PaCO2: arterial carbon dioxide tension PaO,: arterial oxygen tension PCWP: pulmonary
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membrane: i.e., non-cardiogenic pulmonary edema, interstitial and alveolar edema
formation, with a normal plasma oncotic pressure.
This review will highlight an expanded definition ofARDS, the clinical conditions
associated with ARDS, pathophysiology ofthe syndrome, the pathogenesis of acute
lung injury, and current treatments for ARDS (Table 1).
DEFINITION
Ashbaugh and Petty, in their classic article in 1967, described ARDS as a
syndrome of acute respiratory failure, characterized by non-cardiogenic pulmonary
edema with severe hypoxemia caused by right-to-left intrapulmonary shunting
secondary to atelectasis and air space filling from edema fluid [1]. The chest X-ray
showed diffuse pulmonary infiltrates, and there was a decrease in lung compliance;
the lungs required higher than normal airway pressures to deliver a normal tidal
volume.
Hallmarks ofthe syndrome have classically been described as:
1. Hypoxemia: PaO2 less than 8 kPa or 60 mmHg with an FIO2 of0.5 or greater
2. Newpatchy, diffuse, bilateral pulmonary infiltrates on chest X-ray
3. Lowpulmonary compliance
4. Normal left ventricular filling pressures: pulmonary capillary wedge pressure
(PCWP) < 15 mmHg
The incidence of ARDS has been difficult to establish because of lack of agree-
ment on precise definition criteria for its diagnosis. The differences in the reported
incidence of ARDS reflect the various criteria used to establish the diagnosis. U.S.
data from the National Heart, Lung and Blood Institute, published in 1977, esti-
mated an annual 150,000 cases of ARDS, with a mortality of approximately 50-60
percent [2]. The U.S. estimate predicted an annual incidence of60 per 100,000 ofthe
population. A more recent U.K. study predicted an incidence of5 per 100,000 ofthe
population [3]. A prospective study of a homogeneous population in the Canary
Islands reported an incidence of 2-4 per 100,000 population, with a mortality of
approximately 70 percent [4].
Recent data [5] and accompanying editorials [6] have reaffirmed the notion that
mortality rates in ARDS remain in excess of60 percent, essentially unchanged since
the first description of this syndrome by Ashbaugh and Petty. It seems, however,
intuitively obvious to most clinicians that manypatients in riskgroups such as trauma
who develop pulmonary infiltrates and require mechanical ventilation are treated
successfully and survive. Two common criteria-hypoxemia refractory to positive
end-expiratory pressure (PEEP) and simultaneous normal pulmonary artery occlu-
sion pressure-may have introduced a significant selection bias into the definition of
ARDS. The possibility has been considered that entry criteria for ARDS in pub-
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lished studies have increasingly selected an atypical population with a high incidence
ofco-existing multi-system organ failure and an excessively high mortality rate [7].
Much of the controversy concerning ARDS is explained by the lack of a satisfac-
tory definition of the syndrome. The lack of agreed definition has hampered
evaluation of the natural history of the syndrome and its epidemiological and
mortality data and has limited the study of pathophysiologic mechanisms and new
therapeutic interventions.
A major development in defining ARDS has been advanced recently by Murray et
al. [8] in their proposed expanded definition ofthe syndrome. The authors include a
semi-quantitative method for scoring acute lung injury derived, in part, from criteria
used by other investigators. The scoring involves a four-point system: (1) the
impairment ofoxygenation is quantified by the ratio ofarterial oxygen tension to the
fraction of inspired oxygen (PaO2/FIO2); (2) the chest X-ray is scored on the
four-point system; ifthe chest X-ray is clear, then no points are assigned; one to four
points are assigned for consolidation in the four lung zones; (3) the respiratory
compliance may be measured by applying an end-expiratory hold or plateau and the
plateau pressure minus the positive end-expiratory pressure (PEEP) divided by the
tidal volume delivered gives the static pulmonary compliance; (4) the PEEP level-
the PEEP applied may influence arterial oxygenation and provides some indication
ofthe severity ofrespiratory failure (Table 2).
Using this four-point scoring system, the aggregate sum of the number ofcompo-
nents dividedbyfourisused toclassify acutelunginjuryasmild/moderate (0.1 < 2.5)
or severe >2.5. In addition to quantifying the severity of lung injury. Murray's
expanded definition includes an assessment ofwhether the parenchymal lung injury
is acute or chronic and describes the lung injury as being caused by, or associated
with, specific clinical disorders.
CLINICAL CONDITIONS ASSOCIATED WITH ARDS
The expanded definition of ARDS proposed by Murray et al. [8] includes
assessment of the clinical disorders associated with the development of ARDS.
Recent prospective epidemiological studies have identified sepsis syndrome, gastric
aspiration, shock, major trauma, multiple transfusion, acute pancreatitis, drug
overdose, pneumonia, and near-drowning as being the common clinical disorders
associated with the development of ARDS [9]. The risk of developing ARDS
increases with the number of clinical disorders that occur in the same patient. In
addition, the time course for the development of ARDS after the onset of clinical
disorder hasbeen examined. Overall, acute lunginjurydevelopswithin 24 hours in 80
percent of patients at risk who ultimately develop ARDS. Recent prospective data
from Weinberg et al. [10] noted that ARDS developed following sepsis in less than
six hours in manypatients.
Sepsis
Sepsis is the most common clinical disorder associated with the development of
ARDS; 20-40 percent ofpatientswith sepsissyndrome maydevelopARDS [11]. The
relationship between sepsis and ARDS has been the subject ofongoing studies. The
source ofinfection was usually found in the abdomen on autopsy studies in patients
with clinical evidence of infection and positive blood cultures but with an antemor-
tem undetermined site of infection. In contrast, when patients had negative blood
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TABLE 2
Expanded Definition of ARDS
1. Chest radiograph score
No alveolar consolidation
Alveolar consolidation in one quadrant
Alveolar consolidation in two quadrants
Alveolar consolidation in three quadrants
Alveolar consolidation in all four quadrants
2. Hypoxemia score
PaO,/FIO,
PaO2/FIO2
PaO7/FIO2 Pao,/Flo
I
PaO,/FIO,
3. Respiratory system compliance score (when ventilated)
Compliance
Compliance
Compliance
Compliance
Compliance
4. PEEP score (when ventilated)
PEEP
PEEP
PEEP
PEEP
PEEP
0
2
3
4
0
1
2
3
4
.300
225-299
175-224
100-174
<100
80 ml/cmH,O
60-79 ml/cmH,O
40-59 ml/cmH2O
20-39 ml/cmH,O
19 ml/cmH,O
0
1
2
3
4
S5 cmH,O 0
6-8 cmH2O 1
9-11cmH2O 2
12-14 cmH,O 3
215 cmH,O 4
The final value is obtained by dividing the aggregate sum by the number of components that were used:
No lung injury 0
Mild-to-moderate lung injury 0.1-2.5
Severe lung injury (ARDS) > 2.5
Adapted from Murray et al. [8]
cultures and clinical sepsis, the autopsy examination revealed the origin of sepsis to
be in the lung. Montgomery et al. [12] reported that early and late mortality in
patients with ARDS was primarily related to sepsis. Respiratory failure accounted
for 10 percent of the deaths in the first three days following the onset of ARDS and
only 18 percent of delayed mortality. In contrast, sepsis accounted for 30 percent of
the early mortality and 36 percent of the late mortality. Seidenfeld et al. [13]
reported survival rates ofonly 29 percent among 129 patients with ARDS. Sepsis was
more common in the non-survivors, and the lung and abdomen were the most
common sites of infection. Even with appropriate antibiotic therapy, the outcome of
ARDS associated with sepsis was poor.
Aspiration ofGastric Contents
Aspiration of gastric contents is another clinical disorder frequently associated
with ARDS. Acid aspiration or Mendelson's syndrome is a potentially preventable,
iatrogenic complication ofgeneral anesthesia. Many factors predispose to pulmonary
aspiration, but the risk may be reduced by the use of regional anesthesia, where
appropriate, and by the use ofawake endotracheal intubation preceding induction of
anesthesia, in the patient population at risk of developing the syndrome. Pre-
Value Score
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TABLE 3
Factors Affecting Outcome in ARDS
A. Age at the time ofpresentation
B. The route ofdevelopment ofARDS
1. Airway
2. Circulation
C. The severity of the precipitating illness
D. The development of multi-system organ failure
operative use of H2- receptor antagonists to reduce gastric acid production, non-
particulate antacids to neutralize gastric acid, and metoclopramide to increase
peristalsis and promote gastric emptying should minimize the chances ofgastric fluid
oflow pH being aspirated into the tracheobronchial tree in the perioperative period
[14].
Major Trauma
ARDS may develop in trauma victims associated with pulmonary contusion or in
patients with severe hypotension requiring multiple blood transfusions. ARDS
develops in other trauma patients with the development of sepsis syndrome, several
days after the initial presentation. In trauma victims with long bone fractures, fat
embolism syndrome and ARDS may develop 24-48 hours later. Mortality rates of 10
percent for ARDS associated with fat embolism have contrasted with up to 90
percent mortality rates in patients developing ARDS following sepsis. ARDS
patients with fat embolism syndrome, appropriately treated with mechanical ventila-
tion, should have greater than 90 percent survival rates [15].
FactorsAffecting Outcome inARDS
The clinical disorders leading to the development of ARDS clearly influence the
prognosis for recovery. Factors related to mortality in ARDS include: age at the time
ofpresentation; the route ofdevelopment ofARDS, i.e.,via airwayorviacirculation;
the severity of the precipitating illness; the development of multi-system organ
failure (Table 3). The Division of Lung Diseases, Heart, Lung and Blood Institute
study [12] identified age as a significant factor in mortality. Using the criteria of
requirements for F102 of 0.5 and intermittent positive-pressure ventilation for 24
hours or longer, mortality rates of 61 percent for patients less than 65 years old and
82 percent for patients more than 65 years old were reported.
Multi-System Organ Failure
The third part of the expanded definition of ARDS by Murray et al. [8] includes
the specification of organ system failure other than the lung. The importance of
non-pulmonary organ failure has been recognized increasingly in ARDS patients.
Dorinsky et al. [17] recently reviewed the incidence of non-pulmonary organ failure
in patients with ARDS. Abnormalities were most consistently observed in the
kidneys; however, hepatic dysfunction has been reported in as many as 95 percent of
patients with ARDS.
Cardiac Dysfunction
The diagnosis of ARDS involves exclusion of cardiogenic causes of respiratory
failure. Studies have indicated, however, that up to 20 percent of patients with
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TABLE 4
Differential Diagnosis ofARDS
Crystalloid overload
Left ventricular failure
Neurogenic pulmonary edema
Aspiration pneumonia
Overwhelming viral/bacterial pneumonia
ARDS have concomitant cardiac disease. Sepsis maybe associatedwith impaired left
and right ventricular ejection fraction [18]. Concomitant hepatic failure and ARDS
have been associated with especially poor prognosis. Hepatic failure in association
with acute lung injury may have up to 100 percent mortality [17].
RenalImpairment
Renal impairment may be the most commonly associated non-pulmonary organ
failure in patients with ARDS. Mortality rates of 80 percent with ARDS have been
reported if the initial pH remains less than 7.4 following intermittent positive-
pressure ventilation, ifthe initial serum bicarbonate is less than 20mmol/dl-', and if
the initial concentration ofblood urea nitrogen is greater than 23 mmol/l-'. ARDS
patients with these findings have an 80 percent mortality compared with a 40 percent
mortality in patients with normal serum bicarbonate and blood urea nitrogen [5].
Gastrointestinal, central nervous system, and hematological dysfunction may also
commonly be associated with ARDS development.
DifferentialDiagnosis ofARDS
ARDS must be distinguished from other conditions which give rise to similar
X-ray appearances ofpulmonary edema, i.e., fluid overload, left ventricular failure,
neurogenic pulmonary edema, aspiration pneumonia, and overwhelming viral/
bacterial pneumonia (Table 4).
The first clinical sign is usually dyspnea and tachypnea. The earliest laboratory
abnormality is usually a decrease in arterial oxygen tension (PaO2) and possibly a
reduced arterial carbon dioxide tension (PaCO2). As respiratory failure develops,
there is a reduction in PaO2 despite a high inspired oxygen concentration, and there
is evidence of pulmonary edema on chest X-ray, with the added development of
respiratory acidosis. X-ray changes may be absent during the first 12 hours of the
syndrome, and the only finding may be hyperventilation and a reduction in arterial
oxygen tension. The earliest X-ray change is usually interstitial edema. As the
condition worsens, patchy densities develop and progress to the profuse symmetrical
alveolar pattern in both lungs with air-bronchogram appearance.
PATHOPHYSIOLOGY OF ARDS
Acute Phase
Disruption of the alveolar-capillary membrane by a variety ofmechanisms, either
directly through the airway or indirectly via the bloodstream, has been implicated as
the pathophysiological mechanism responsible for ARDS development. In the early
phase of acute respiratory failure, patients typically manifest severe alveolar edema,
with large numbers ofinflammatory cells, primarily neutrophils, in the air spaces and
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interstitium of the lungs. Initially, the edema fluid has a high concentration of
protein, which is characteristic of an increased-permeability pulmonary edema. In
addition, the epithelial injury in the acute phase of ARDS has recently been
highlighted. Epithelial injury is now emerging as a very important component of the
acute lung injury, partly because injury to the epithelium lowers the threshold for
alveolar flooding and results in a substantial deterioration in gas exchange.
Recent data have suggested that the presence or absence of normal alveolar
epithelial function, as measured by sequential concentrations of protein in pulmo-
nary edema fluid, maybe an important prognostic indicator in ARDS patients [19]. If
patients absorb excess alveolar fluid within the first 12 hours after developing
pulmonary edema, alveolar epithelial function may remain reasonably intact, and
recovery prospects are improved. In contrast, patients who manifest no change in
pulmonary edema fluid protein concentration, in the first 12 hours after the onset of
mechanical ventilation, may have higher mortality rates. Pleural effusions may be
noted in 40 percent of patients with increased-permeability pulmonary edema [11].
Approximately 20-25 percent of the excess lung water in ARDS that accumulates
within the first few hours may drain into the pleural space and is cleared from the
thoracic cavity by pleural lymphatics. The pleural space is an important route for the
clearance ofa significant fraction ofpulmonary edema fluid.
Subacute Phase
The subacute phase of ARDS occurs approximately from days 5 to 10 after lung
injury and primarily involves the interstitium of the lung. Some patients develop an
acceleratedfibrosingalveolitis. Ultrastructural studies have shown extensive prolifer-
ation of the alveolar type II epithelial cells, apparently in response to injury of the
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type 1 epithelial cells in the acute phase [20]. There is a pronounced increase in
fibroblast and collagen formation in the interstitium. Considerable interest has
focused on the role of the fibroblast and epithelial growth factors, which may be
released from macrophages or other cells in the lungs, as mechanisms for the
responses to acute lung injury. The highest risk of infection appears to be in the first
six to ten days after the initiation ofventilation [21]. The destruction of lung tissue
results in an impairment ofboth blood and lymphatic drainage, and the presence of
cellular debris and plasma in the airway, with impaired mucociliary transport, may
predispose to secretion retention and the development ofpneumonia.
Chronic Phase
Lung destruction may occur during the chronic phase of ARDS 10-14 days after
the onset of the syndrome. Varying degrees of lung destruction, emphysema, and
pulmonaryvascular obliteration, in addition to areas offibrosis, may develop. In this
chronic phase, patients may have lesser degrees of oxygenation impairment and
lesser PEEP requirements; these patients continue to have high dead space and high
minute ventilation requirements. Lung compliance may be decreased secondary to
pulmonary fibrosis and diminished surfactant synthesis.
Pulmonary function studies of ARDS survivors have demonstrated that many
patients who recover from the syndrome have normal to near-normal pulmonary
function. Some patients with no previous history of reactive airway disease or no
prior history ofsmokingmay, however, develop reactive airway disease after recovery
from ARDS [22]. Studies ofARDS survivors have indicated that patients who were
bacteremic during their illness had a greater decrease in their diffusion capacity
following recovery. There is no correlation between recovery of pulmonary function
and the duration of mechanical ventilation, the inspired concentration of oxygen
utilized, and the period forwhich supplementary oxygen was required. Other studies
have noted a correlation between post-ARDS pulmonary function and the maximal
pulmonary artery pressures, the lower pulmonary compliance, and the maximum
PEEP required during the patient's illness [23].
PATHOGENESIS OF ARDS
Several mediators, both locally in the lung and in the systemic circulation, have
been implicated as being responsible for the pathophysiological changes associated
with ARDS (Table 5). Much recent interest has focused on the complex interaction
ofcirculating and resident lungcells in the pathophysiology ofthe syndrome. Interest
has centered on the role ofneutrophils, plateletes, cytokines derived from mononu-
clear cells and macrophages, the complement system, prostaglandins/leukotrienes,
oxygen-derived radicals, and avariety ofproteases.
Neutrophils
Neutrophil function may be divided into four phases: adherence, chemotaxis,
phagocytosis, and triggering of post-phagocytic intercellular events designed to
destroy ingested microorganisms [11].
There is considerable evidence to implicate the neutrophil in the initial lung
damage in patients who develop ARDS. Proponents of neutrophil-related lung
injury claim that peripheral leucopenia is associated with ARDS [24] because of
complement-activated neutrophil accumulation in the lung [25]. Large numbers of
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TABLE 5
Pathogenesis ofARDS: Current Postulates
Circulating Cell
Neutrophils
Platelets
Monocytes
Resident Lung Cells
Alveolar macrophages
Intravascular macrophages
Epithelial cells
Mediators
Complement activation
Cytokines:
Tumor necrosis factor
Interleukin 2
Prostaglandins
Oxygen-derived radicals
Proteases
neutrophils collect in the lung in the early phases of lung injury. Under these
circumstances, neutrophils may be present in a functionally and metabolically
activated state. The chemotactic responses of neutrophils in patients with ARDS
maybe increased when compared with control patients. Activated neutrophils which
sequester in the pulmonary circulation may release toxic oxygen free radicals,
proteolytic enzymes, and products of arachidonic acid cascade, which damage the
pulmonary microvascular endothelial cells and cause the increased permeability of
pulmonary capillaries [26].
Other investigators, however, have failed to establish a relationship between
leucopenia and the development ofARDS. Investigators have reported the develop-
ment ofARDS in patients with severe neutropenia after chemotherapy [27]. There
maybebothneutrophil-dependent andneutrophil-independent mechanisms respon-
sible for the initial lung injury.
Platelets andDisseminatedIntravascular Coagulation
Platelet abnormalities and activation of the coagulation cascade have been impli-
cated in the pathogenesis of ARDS. In a study of septic patients at risk for the
development of ARDS, a platelet count of less than 100,000 mm-3 was associated
with an increased risk of ARDS development. The study also demonstrated signifi-
cant platelet sequestration in the reticuloendothelial system in these patients [28].
Thrombocytopenia, intravascularmicrothrombosis, and decreasedfibrinolysis have
all been implicated in the pathogenesis of ARDS [29]. Depressed fibrinolysis
associated with inhibition of plasmin and plasminogen activator have also been
reported [30]. Coagulation disorders, including thrombocytopenia and intravascular
coagulation, may be associated with ARDS; however, these disorders may also be
associated with sepsis and major trauma. Platelet and coagulation abnormalities are
not reliable specific predictors for the development ofARDS.
Complement System
Complement activation has been implicated in the pathogenesis ofthe acute lung
injury associated with ARDS. In particular, C3a and C5a, potent neutrophil chemo-
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tactic stimulants, have been found in excess quantities in bronchoalveolar lavage
fluid obtained from patients with ARDS [31]. The degree ofcomplement activation
has been reported to be predictive of the development of ARDS [32]. Other
investigators have noted increased concentration of C5a in patients with sepsis, but
levels did not predict the development of lung injury. The concentration ofC5a may
correlate better with hypotension and metabolic acidosis than with the eventual
development of acute lung injury [33]. Complement activation may be part of the
pathophysiological process during sepsis which leads to systemic and pulmonary
endothelial injury but may not be the sole factor responsible for the development of
lung injury.
Cytokines
Considerable recent attention has focused on the possible contribution of a
number of cytokines in the development of acute lung injury [11]. Tumor necrosis
factor, a peptide produced by mononuclear cells in response to endotoxin and
interleukin 2, reproduces the physiological changes, e.g., hypotension and metabolic
acidosis, associatedwith septicshocksyndrome [34]. The macrophage isprobablythe
principal cell involved in mediating the effects of endotoxin, and the elaboration by
macrophages of tumor necrosis factor may be a crucial response to sepsis [35].
Monocytes may alsoproduce avarietyofinterleukinswhich exaggerate the inflamma-
tory response. In addition, alveolar macrophages secrete a variety of factors which
sequester neutrophils in the lungs, and which may contribute to the development of
ARDS [36]. Intravascular pulmonary macrophages may have an important effect in
modulating acute lung injury. The release of intracellular products of intravascular
macrophages may contribute to the increased pulmonary endothelial and epithelial
permeability characteristic ofARDS [11].
Prostaglandins/Oxygen Radicals/Proteases and OtherMediators
Cyclo-oxygenase and lipoxygenase by-products of arachidonic acid metabolism
have been extensively investigated as agents mediating the acute lung injury associ-
ated with ARDS. Experimental studies have implicated cyclo-oxygenase products in
mediating the initial pulmonary hypertension as well as the bronchoconstriction
which may occur following endotoxin infusion [37]. Other clinical studies have
reported substantial quantities of the lipoxygenase product leukotriene D4 in
bronchoalveolar lavage and pulmonary edema fluid ofpatientswith ARDS [38]. The
role of prostaglandin in mediating the pathological changes in ARDS may be
clarified if studies ofprostaglandin metabolism inhibitors indicate a beneficial effect
on alveolar gas exchange and morbidity. Preliminary data suggest that ibuprofen, a
cyclo-oxygenase inhibitor, produces a modest improvement in oxygenation in some
patients with ARDS [38].
Recent studies have focused on the role of oxygen-derived radicals from neutro-
phils and platelets in the pathogenesis ofARDS and the role of oxygen free radical
scavengers in the treatment of the syndrome. In addition to neutrophils and
platelets, oxygen free radical production maybe associated with high inspired oxygen
administration and reperfusion of hypoxic tissues. The anti-oxidants superoxide
dismutase, catalase, and glutathione peroxidase may reduce the concentrations of
toxic oxygen free radicals and may have a role in the prevention and therapy of
ARDS.
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A variant of proteolytic enzymes, e.g., elastase, hyaluronidase, and plasminogen
activator derived from granulocytes and mononuclear cells, may disrupt the capillary
endothelium and increase vascular permeability.
CURRENT TREATMENTS FOR ARDS
The objectives of current treatment strategies in ARDS are to increase tissue
oxygen delivery by increasing arterial oxygen tension and cardiac output while
simultaneously attenuating the pulmonary and systemic injury by appropriate phar-
macologic and surgical interventions.
Increased Oxygen Delivery
In many patients with ARDS, a combination of hypoxemia and decreased cardiac
output produces critical reductions in tissue oxygen delivery (DO2). In ARDS
patients, hypotension and low cardiac output may be associated with hypovolemia
due to major trauma or PEEP-induced reductions in venous return; decreased
myocardial contractility due to pre-existing heart disease or the effect of sepsis on
myocardial contractility and sepsis-induced changes in systemic vascular resistance.
FluidManagement inARDS
The aims offluid management inARDS are to maintain adequate organ perfusion
and nutrition without increasing pulmonary extravascular fluid which, in turn, may
aggravate pulmonary gas exchange.
The factors which influence the choice of intravenous fluid are determined by the
differences in hydrostatic pressure between the pulmonary capillary and the intersti-
tial space; the difference in oncotic pressure between these two spaces and the effect
of lung injury on the reflection coefficient (which determines the amount of sub-
stances of large molecular weight which leak through capillaries) [11]. The most
significant treatment option is to maintain low capillary pressures, thereby reducing
the hydrostatic transcapillary pressure gradient. This reduction must be commensu-
rate with adequate organ perfusion. Volume expansion with blood, in the first
instance, to maintain an adequate hematocrit (approximately 0.4) is the first step in
the correction ofhypovolemia. Thereafter, colloids are more effective in maintaining
circulating blood volume than crystalloids. Of the available colloids, albumen
hetastarch and pentastarch are the longest-acting, while polygeline solutions are
short-acting and effectively become crystalloids eight to 12 hours later.
Cardiac OutputAugmentation
Pre-existing cardiac disease and sepsis-induced reductions in ventricular ejection
fraction may require specific inotropic support. Recent data by Shoemaker [39]
suggest that pharmacological augmentation of cardiac index and oxygen delivery,
e.g., cardiac index greater than 4.5 l/m-2 and increased DO2 and VO2, may reduce
cardiorespiratory complications in high-risk surgical patients. Improved oxygen
delivery in these patients may improve organ perfusion and thereby reduce the
incidence ofmulti-system organ failure. In other studies, cardiac output and oxygen
consumption in patients with sepsis were improved by vasopressor therapy, but
mortality was no better than in patients treated with intravenous fluids alone [40].
Further studies to confirm the possible benefit of therapy directed at improving
oxygen delivery in patients with ARDS are indicated.
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IncreasedImprovingArterial Oxygen Tension
The persistently high mortality rates of60-70 percent in patientswith ARDS have
provoked recurring interest in new techniques of providing mechanical ventilation
for patients with ARDS. Most studies have, however, shown that mortality in ARDS
patients may be attributed to sepsis and multi-system organ failure rather than
primarily to respiratory failure.
Innovations in techniques ofmechanical ventilation have included extracorporeal
membrane oxygenation (ECMO); high-frequency jet ventilation; pressure-con-
trolled, inverse-ratio ventilation; and, most recently, extracorporeal carbon dioxide
removal. Zapol et al. [41] in the ECMO study published in 1979 compared a control
group treated with conventional mechanicalventilationwith ECMO-treated patients
who received lower tidal volumes and mean airway pressures. Similar high mortality
rates of 90 percent with similar incidence of barotrauma were reported in the two
groups. In the early 1980s, high-frequency ventilation was advocated as an alterna-
tive to conventional ventilation, partly because lower peak airway pressures could be
employed, which might result in less barotrauma and less ventilation-induced lung
injury. Subsequent data indicated, however, that significant improvements in oxygen-
ation could be achieved with high-frequency jet ventilation only in association with
increased mean airway pressures, which, in turn, had deleterious effects on venous
return and cardiac output [42]. In a well-designed prospective randomized study of
309 patients, Carlon et al. [43] noted no significant difference in the total duration of
intensive care or survival in patients treated with high-frequency jet ventilation
compared with conventional volume-controlled ventilation. More recently, MacIn-
tyre et al. [44] concluded that high-frequency jet ventilation offers no important
clinical benefits compared with conventional intermittent positive-pressure ventila-
tion in adult patients with ARDS, with the possible exception of those patients with
large bronchopleural fistulae.
Recent interest has focused on the use of pressure-controlled, inverse-ratio
ventilation as an alternative to conventional volume-controlled ventilation in pa-
tients with ARDS. Tharrat et al. [45] published a retrospective study of the use of
pressure-controlled, inverse-ratio ventilation in 31 patients with severe ARDS. This
ventilatory technique was reported to be associated with significant reduction in
minute ventilation, peak inspiratory pressure, PEEP, and some improvement in
arterial oxygenation. There was, however, an overall mortality of77 percent in the 31
patients with ARDS. A significant increase in mean airway pressure was noted, and
pneumothorases developed in six of the 31 patients studied. A recent Italian study
reported favorable outcome with veno-veno extracorporeal membrane carbon diox-
ide removal with low-frequency positive-pressure ventilation in 47 patients with
ARDS [46]. Veno-veno extracorporeal membrane carbon dioxide removal is cur-
rently the subject of a prospective study centered at the University of Utah in Salt
Lake City [47].
CPAP/PEEP
Continuous positive airway pressure (CPAP) and positive end-expiratory pressure
(PEEP) are believed to have several therapeutic effects in ARDS. They may reverse
progressive alveolar collapse and reduce interstitial edema, thereby improving
alveolar gas exchange and increasing arterial oxygen tension. CPAP and PEEP may
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effectively increase the functional residual capacity, increase PaO2, and decrease the
magnitude of intrapulmonary shunt [48]. The appropriate methods of CPAP/PEEP
delivery are difficult to determine, but decreasing intrapulmonary shunt with in-
creased arterial oxygen tension, improving pulmonary compliance and oxygen trans-
port have all been used to identify the "best PEEP" level [49]. The beneficial effects
of CPAP/PEEP are not without potential side effects. Venous return may be
decreased because of increased intrathoracic pressure, resulting in decreased car-
diac output. Increased mean airway pressure predisposes to barotrauma. The
detrimental effects ofPEEP are most pronounced in hypovolemic patients.
The appropriate level of PEEP is still disputed. Early initial enthusiasm that
suggested improved survival in ARDS with PEEP was subsequently disputed when
randomized studies of increased versus moderate levels found no significant differ-
ences between the two groups in terms of duration of mechanical ventilation or
overall mortality rates [50]. The use of prophylactic PEEP in patients at risk of
ARDS also remains controversial. A prospective study of the prophylactic use of 8
cm H20 PEEP inpatients at high riskfor developing ARDS proved that such use was
of no benefit in preventing acute lung injury [51]. There is no evidence that PEEP
hastens the recovery from lung injury, prevents the development of lung injury, or
reduces extravascular lung water. Alveolar edema is primarily dissolved by an active
sodium transport, which may not depend on the mode of ventilation but on the
airway pressure.
The mainstay ofcurrent management ofARDS is to maintain the arterial oxygen
tension greater than 8 Kpa or 60 mmHg, utilizing as low as possible inspired oxygen
concentration, with thejudicious use ofPEEP and optimum tidal volume.
Pharmacological Interventions
ARDS may be considered as the pulmonary manifestation of multi-organ failure
(MOF) syndrome. The death rate forARDS is closely related to the numberofother
organ systems that fail. Pharmacological intervention for ARDS may prevent multi-
organ failure and, if given to high-risk patients, may also prevent the occurrence of
ARDS.
Corticosteroids have been the most widely used drugs in ARDS because of their
established anti-inflammatory properties [52]. These drugs have been shown to
reduce lung injury in experimental studies. Corticosteroids have been reported to
improve outcome in patients with fat embolism; however, all other recent large-scale
prospective studies have failed to demonstrate a benefit in terms ofprevention of, or
outcome from, ARDS [53].
Several new therapies aimed at reducing white cell chemotaxis/activation or
altering the balance of inflammatory mediators are currently under investigation.
These agentsinclude non-steroidal anti-inflammatory agents,vasodilatoryprostaglan-
dins, PGE/PGI immunotherapy [54], andphentoxifylline. All these agents have been
shown to influence specific aspects of this syndrome, but large-scale studies of
outcome are keenly awaited.
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